Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Liquidity is very important for biotech stocks, mostly because many of them are not producing earnings and must rely on sources of liquidity to sustain operations.

We ran a screen on the biotech industry for stocks seeing the most significant growth in liquidity over the past 10 years, with 10-year compound annual growth rates in current assets exceeding that in current liabilities by at least 5%.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬


We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these companies have sustainable operations? Use this list as a starting point for your own analysis.

1. Corcept Therapeutics Inc. (NASDAQ:CORT): Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. 10-year CAGR of current assets at 37.78% vs. 12.00% 10-year CAGR for current liabilities.

2. Hi Tech Pharmacal Co. Inc. (NASDAQ:HITK): Develops, manufactures, markets and sells generic, prescription, over-the-counter and nutritional products in liquid and semisolid dosage forms in the United States. 10-year CAGR of current assets at 23.78% vs. 15.50% 10-year CAGR for current liabilities.

3. Myriad Genetics Inc. (NASDAQ:MYGN): Focuses on the development and marketing of novel predictive medicine, personalized medicine and prognostic medicine products. 10-year CAGR of current assets at 11.79% vs. 0.54% 10-year CAGR for current liabilities.

4. Questcor Pharmaceuticals, Inc. (QCOR): Provides prescription drugs for central nervous system and inflammatory disorders. 10-year CAGR of current assets at 36.57% vs. 19.85% 10-year CAGR for current liabilities.

5. QLT Inc. (NASDAQ:QLTI): Engages in the development and commercialization of therapies for the eye. 10-year CAGR of current assets at 0.45% vs. -5.86% 10-year CAGR for current liabilities.

6. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Engages in the discovery and development of small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. 10-year CAGR of current assets at 12.65% vs. 3.47% 10-year CAGR for current liabilities.

7. Techne Corp. (NASDAQ:TECH): TECHNE Corporation and its subsidiaries engage in the development, manufacture and sale of biotechnology products and hematology calibrators and controls primarily in the United States and Europe. 10-year CAGR of current assets at 6.38% vs. 1.36% 10-year CAGR for current liabilities.

8. Valeant Pharmaceuticals International, Inc. (NYSE:VRX): Develops, manufactures and markets pharmaceutical products in the areas of neurology, dermatology and branded generics. 10-year CAGR of current assets at 14.63% vs. 9.26% 10-year CAGR for current liabilities.

9. VIVUS Inc. (NASDAQ:VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. 10-year CAGR of current assets at 19.49% vs. 0.27% 10-year CAGR for current liabilities.

*Data sourced from Screener.co.

Source: 9 Biotech Stocks With Significant Liquidity Growth